UK regulator approves Eli Lilly’s once‑weekly insulin Onswik for type 2 diabetes
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation in the United Kingdom for Eli Lilly’s once‑weekly basal insulin, Onswik (insulin efsitora alfa). The approval follows a rigorous assessment that found the product provides glycaemic control comparable to daily basal insulins. The drug reduces injection frequency from 365 to 52 per year, a benefit highlighted by NICE earlier this year.
Why it matters
The authorisation enables Eli Lilly to launch Onswik in the UK market, expanding its diabetes portfolio and creating a new revenue stream. Investors can expect the product to capture patients who prefer fewer injections, potentially boosting sales in the region.
Key facts
- 1The MHRA granted authorisation for Onswik (insulin efsitora alfa) in the United Kingdom. marketscreener.com
- 2Onswik is a long‑acting basal insulin designed for once‑weekly injection. marketscreener.com
- 3Clinical trial data showed glycaemic control comparable to once‑daily basal insulin treatments. nursinginpractice.com
- 4The weekly regimen reduces injections from 365 per year to 52 per year. nursinginpractice.com
- 5NICE recommended the treatment earlier in the year, pending the licensing granted to Eli Lilly. nursinginpractice.com
- 6The most commonly reported adverse reaction is hypoglycaemia. nursinginpractice.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.